Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia

Autor: Lori C. Guthrie, Patrick K. Kelley, Young H. Lim, Richard P. Lifton, Michael Gottschalk, Michael T. Collins, John D. Overton, Ann Maruri, Edward W. Cowen, Moise L. Levy, Harald Jüppner, Shrikant Mane, Cynthia M. C. Deklotz, William A. Gahl, Rachel I Gafni, Jeffrey S. Sugarman, Keith A. Choate, Nisan Bhattacharyya, Diana Ovejero, Alison M. Boyce, Erin C. Loring, Lawrence F. Eichenfield, Cynthia J. Tifft, Gretchen Golas
Rok vydání: 2013
Předmět:
Neuroblastoma RAS viral oncogene homolog
Male
Kidney Disease
Skin Neoplasms
Hypophosphatemia
urologic and male genital diseases
Medical and Health Sciences
GTP Phosphohydrolases
2.1 Biological and endogenous factors
Developmental
Exome
Aetiology
Child
Genetics (clinical)
Skin
Genetics & Heredity
Osteomalacia
Nevus
Pigmented

integumentary system
Gene Expression Regulation
Developmental

General Medicine
Articles
Melanocytic nevus
Biological Sciences
Female
Activating RAS Mutation
Sequence Analysis
Adolescent
1.1 Normal biological development and functioning
Biology
Proto-Oncogene Proteins p21(ras)
Rare Diseases
Congenital melanocytic nevus
Pigmented
Underpinning research
medicine
Genetics
Nevus
Humans
HRAS
Molecular Biology
Membrane Proteins
DNA
Sequence Analysis
DNA

medicine.disease
Fibroblast Growth Factors
stomatognathic diseases
Fibroblast Growth Factor-23
Gene Expression Regulation
Mutation
Cancer research
Zdroj: Human molecular genetics, vol 23, iss 2
ISSN: 1460-2083
Popis: Pathologically elevated serum levels of fibroblast growth factor-23 (FGF23), a bone-derived hormone that regulates phosphorus homeostasis, result in renal phosphate wasting and lead to rickets or osteomalacia. Rarely, elevated serum FGF23 levels are found in association with mosaic cutaneous disorders that affect large proportions of the skin and appear in patterns corresponding to the migration of ectodermal progenitors. The cause and source of elevated serum FGF23 is unknown. In those conditions, such as epidermal and large congenital melanocytic nevi, skin lesions are variably associated with other abnormalities in the eye, brain and vasculature. The wide distribution of involved tissues and the appearance of multiple segmental skin and bone lesions suggest that these conditions result from early embryonic somatic mutations. We report five such cases with elevated serum FGF23 and bone lesions, four with large epidermal nevi and one with a giant congenital melanocytic nevus. Exome sequencing of blood and affected skin tissue identified somatic activating mutations of HRAS or NRAS in each case without recurrent secondary mutation, and we further found that the same mutation is present in dysplastic bone. Our finding of somatic activating RAS mutation in bone, the endogenous source of FGF23, provides the first evidence that elevated serum FGF23 levels, hypophosphatemia and osteomalacia are associated with pathologic Ras activation and may provide insight in the heretofore limited understanding of the regulation of FGF23.
Databáze: OpenAIRE